CLINICAL, IMAGING AND PATHOLOGICAL ASPECTS OF MAMMARY LYMPHOMAS SECONDARY TO MALIGNANT T- CELL CUTANEOUS LYMPHOMAS
Keywords:imaging aspects, secondary breast lymphoma, mycosis fungoides
Primary cutaneous lymphomas rank as the second most common clinical form of extranodal non-Hogdkin malignant lymphomas. Among non-Hodgkin malignant skin T-cell lymphomas, Mycosis Fungoides (MF) is the most frequent clinical occurence. The MF lymphoma originates in skin-homing helper T-cells, which express the CD4 + marker, showing chronic evolution, with recurrent lesions. In advanced stages, patients with Mycosis Fungoides may experience severe/extensive skin lesions or extracutaneous localizations of the disease. The secondary breast lymphoma is more common in non-Hodgkin malignant lymphoma than in Hodgkin lymphoma. Among the mammographic characteristics of breast lymphoma we mention: oval or round tumor mass, with well-defined or indistinct margins, absence of intratumoral calcifications, presence of intramammary lymph nodes, supra-adjacent skin thickening and lymphedema that causes diffuse increase in breast density. The ultrasound features of breast lymphoma run as follows: it is oval or round in shape, with well-defined or indistinct margins, which in Doppler ultrasound are identified as hypervascularized masses. The description of the imaging features of mammary lymphomas secondary to cutaneous T-cell lymphomas is required before performing the breast core-needle biopsy.
Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Research. 2016;5.
Amorim GM, Niemeyer?Corbellini JP, Quintella DC, Cuzzi T, Ramos?e?Silva M. Hypopigmented mycosis fungoides: a 20?case retrospective series. International journal of dermatology. 2018;57(3):306-12.
Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, Glassman SJ, Sasseville D, et al. Environmental and other extrinsic risk factors contributing to the pathogenesis of cutaneous T cell lymphoma (CTCL). Frontiers in oncology. 2019;9:300.
Akinbami AA, Osikomaiya BI, John-Olabode SO, Adediran AA, Osinaike O, Uche EI, et al. Mycosis fungoides: case report and literature review. Clinical Medicine Insights: Case Reports. 2014;7:CCRep. S15724.
Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov IV, Iversen L, et al., editors. Malignant inflammation in cutaneous T?cell lymphoma-a hostile takeover. Seminars in immunopathology; 2017: Springer.
Cerroni L. Lymphoproliferative lesions of the skin. Journal of clinical pathology. 2006;59(8):813-26.
Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. The American journal of pathology. 1985;119(2):315.
Jennings WC, Baker RS, Murray SS, Howard CA, Parker DE, Peabody LF, et al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Annals of surgery. 2007;245(5):784.
Anne N, Pallapothu R. Lymphoma of the breast: a mimic of inflammatory breast cancer. World journal of surgical oncology. 2011;9(1):1-4.
Hoimes CJ, Selbst MK, Shafi NQ, Rose MG, Rosado MF. Hodgkin's lymphoma of the breast. Journal of Clinical Oncology. 2010;28(2):e11-e3.
Zack JR, Trevisan SG, Gupta M. Primary breast lymphoma originating in a benign intramammary lymph node. American Journal of Roentgenology. 2001;177(1):177-8.
Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology. 2007;245(3):692-702.
Shim E, Song SE, Seo BK, Kim Y-S, Son GS. Lymphoma affecting the breast: a pictorial review of multimodal imaging findings. Journal of breast cancer. 2013;16(3):254.
Harvey NT, Spagnolo DV, Wood BA. 'Could it be mycosis fungoides?': an approach to diagnosing patch stage mycosis fungoides. Journal of Hematopathology. 2015;8(4):209-23.
Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. The American journal of surgical pathology. 1995;19(12):1423-30.
Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. Journal of the American Academy of Dermatology. 2002;47(6):914-8.
Tebeic? T, Andrei R, Zurac S, St?niceanu F. Practical aspects regarding the histopathological diagnosis of early mycosis fungoides. Romanian Journal Of Internal Medicine. 2016;54(1):3-10.
Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. Journal of the American Academy of Dermatology. 2005;53(6):1053-63.
Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Archives of dermatology. 2003;139(7):857-66.
Vonderheid E, Bigler R, Hou J. On the possible relationship between staphylococcal superantigens and increased Vbeta5. 1 usage in cutaneous T-cell lymphoma. The British journal of dermatology. 2005;152(4):825-6; author reply 7.
Morales M, Olsen J, Johansen P, Kaerlev L, Guénel P, Arveux P, et al. Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. European journal of cancer. 2003;39(4):511-6.
Kelati A, Gallouj S, Tahiri L, Harmouche T, Mernissi F. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. International journal of women's dermatology. 2017;3(2):100-6.
Sanchez JL, Ackerman A. The patch stage of mycosis fungoides. Criteria for histologic diagnosis. The American Journal of Dermatopathology. 1979;1(1):5-26.
Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. The American journal of surgical pathology. 2000;24(1):40.
Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. The Lancet. 2008;371(9616):945-57.
Michie S, Abel E, Hoppe R, Warnke R, Wood G. Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. The American journal of pathology. 1990;137(6):1447.
Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe RT, Warnke RA, et al. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sezary syndrome relative to normal blood values. Journal of the American Academy of Dermatology. 1990;22(4):602-7.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, The Journal of the American Society of Hematology. 2011;117(19):5019-32.
Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer. 1972;29(6):1705-12.
Moura C, Leite MI, Parreira R, Medeiros A. Primary breast lymphoma. Journal of surgical case reports. 2020;2020(1):rjz405.
Kim YR, Kim HS, Kim H-W. Are irregular hypoechoic breast masses on ultrasound always malignancies?: a pictorial essay. Korean journal of radiology. 2015;16(6):1266.
Raj SD, Shurafa M, Shah Z, Raj KM, Fishman MD, Dialani VM. Primary and secondary breast lymphoma: clinical, pathologic, and multimodality imaging review. Radiographics. 2019;39(3):610-25.
Melo A, Silva S, Ferreira C, Pereira R, Esteves A, Marques RA, et al. Primary breast lymphoma: A mimic of inflammatory breast cancer. International journal of surgery case reports. 2018;53:410-3.
Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood, The Journal of the American Society of Hematology. 2012;119(7):1643-9.
Liberman L, Giess CS, Dershaw DD, Louie DC, Deutch BM. Non-Hodgkin lymphoma of the breast: imaging characteristics and correlation with histopathologic findings. Radiology. 1994;192(1):157-60.
Dimitrov DD, Karamanliev MP, Deliyski TS, Gabarski AV, Vatov PP, Gencheva RO, et al. Diagnostic value of tru-cut biopsy in diagnosing breast lesions. Journal of Biomedical and Clinical Research. 2016;9(2):126-9.
Apesteguía L, Pina LJ. Ultrasound-guided core-needle biopsy of breast lesions. Insights into imaging. 2011;2(4):493-500.
Copyright (c) 2021 Medico Science Press
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work by Medico Science Press is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Medico Oncology is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute or share alike, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.